Search

Your search keyword '"Trexler M"' showing total 66 results

Search Constraints

Start Over You searched for: Author "Trexler M" Remove constraint Author: "Trexler M" Database MEDLINE Remove constraint Database: MEDLINE
66 results on '"Trexler M"'

Search Results

1. Improving Timely Administration of Essential Outpatient Medications in a Pediatric ED.

2. Arginines of the CGN codon family are Achilles' heels of cancer genes.

3. Evolution of termination codons of proteins and the TAG-TGA paradox.

4. Use of Publication Dynamics to Distinguish Cancer Genes and Bystander Genes.

5. Wnt Inhibitory Factor 1 Binds to and Inhibits the Activity of Sonic Hedgehog.

6. Avidin-biotin complex-based capture coating platform for universal Influenza virus immobilization and characterization.

7. Use of signals of positive and negative selection to distinguish cancer genes and passenger genes.

8. High-performance chemical- and light-inducible recombinases in mammalian cells and mice.

9. Analysis of Tks4 Knockout Mice Suggests a Role for Tks4 in Adipose Tissue Homeostasis in the Context of Beigeing.

10. Structure, function and disease relevance of Wnt inhibitory factor 1, a secreted protein controlling the Wnt and hedgehog pathways.

11. Applications of Raman spectroscopy in cancer diagnosis.

12. Morphological Stasis and Proteome Innovation in Cephalochordates.

13. Influence of WFIKKN1 on BMP1-mediated activation of latent myostatin.

14. Influence of collagen source on fibrillar architecture and properties of vitrified collagen membranes.

15. K153R polymorphism in myostatin gene increases the rate of promyostatin activation by furin.

16. Emerging technology: applications of Raman spectroscopy for prostate cancer.

17. Banded structures in collagen vitrigels for corneal injury repair.

18. Free-volume hole relaxation in molecularly oriented glassy polymers.

19. Both LCCL-domains of human CRISPLD2 have high affinity for lipid A.

20. Latent myostatin has significant activity and this activity is controlled more efficiently by WFIKKN1 than by WFIKKN2.

21. Synthesis and properties of regenerated cellulose-based hydrogels with high strength and transparency for potential use as an ocular bandage.

22. A novel COCH mutation associated with autosomal dominant nonsyndromic hearing loss disrupts the structural stability of the vWFA2 domain.

23. Rationale for the diabetic retinopathy clinical research network treatment protocol for center-involved diabetic macular edema.

24. Verification and implementation of a modified split Hopkinson pressure bar technique for characterizing biological tissue and soft biosimulant materials under dynamic shear loading.

25. Biological functions of the WAP domain-containing multidomain proteins WFIKKN1 and WFIKKN2.

27. Reassessing domain architecture evolution of metazoan proteins: major impact of gene prediction errors.

28. WFIKKN1 and WFIKKN2 bind growth factors TGFβ1, BMP2 and BMP4 but do not inhibit their signalling activity.

29. Effects of ranibizumab on exudative disciform scars.

30. The second von Willebrand type A domain of cochlin has high affinity for type I, type II and type IV collagens.

31. NMR solution structure of the neurotrypsin Kringle domain.

32. Both WFIKKN1 and WFIKKN2 have high affinity for growth and differentiation factors 8 and 11.

33. Diurnal variation in retinal thickening measurement by optical coherence tomography in center-involved diabetic macular edema.

34. Preoperative visual acuity as a prognostic indicator for laser treatment of macular edema due to branch retinal vein occlusion.

35. A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema.

36. Second Kunitz-type protease inhibitor domain of the human WFIKKN1 protein.

37. Multiple laser treatments for macular edema attributable to branch retinal vein occlusion.

38. Hydroxamate-based peptide inhibitors of matrix metalloprotease 2.

40. Gene Symbol: COCH. Disease: DFNA9.

41. A novel COCH mutation, V104del, impairs folding of the LCCL domain of cochlin and causes progressive hearing loss.

42. NMR structure of the netrin-like domain (NTR) of human type I procollagen C-proteinase enhancer defines structural consensus of NTR domains and assesses potential proteinase inhibitory activity and ligand binding.

43. Expression, purification and characterization of the second Kunitz-type protease inhibitor domain of the human WFIKKN protein.

44. Peptide ligands for the fibronectin type II modules of matrix metalloproteinase 2 (MMP-2).

45. Endogenous endophthalmitis after routine dental cleaning.

46. Expression and characterization of the olfactomedin domain of human myocilin.

47. Structural characterization of the second TSP1-module of human thrombospondin.

48. Distinct expression pattern of two related human proteins containing multiple types of protease-inhibitory modules.

49. Origin of fibronectin type II (FN2) modules: structural analyses of distantly-related members of the kringle family idey the kringle domain of neurotrypsin as a potential link between FN2 domains and kringles.

50. NMR structure of the LCCL domain and implications for DFNA9 deafness disorder.

Catalog

Books, media, physical & digital resources